Active — Not RecruitingNot Applicable

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

South Korea150 participantsStarted 2025-06-05

Plain-language summary

This study is to assess the safety and effectiveness of Elranatamab in the real-world clinical settings for the treatment of patients with multiple myeloma in Korea.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who have been prescribed ELREXFIO (Elranatamab) by their physician as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. * Patients with evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: * Patients with contraindication according to locally approved label of ELREXFIO (Elranatamab) * Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of an adverse event (AE)/ adverse drug reaction (ADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of a serious AE (SAE)/ serious ADR (SADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of an unexpected AE (UAE)/ unexpected ADR (UADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of a serious unexpected AE (SUAE)/ serious unexpected ADR (SUADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of an adverse event special interest (AESI)

Timeframe: At least 28 days from the last dose of Elranatamab

Trial details

NCT IDNCT06581848

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-01-31

View on ClinicalTrials.gov More Multiple Myeloma trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Incidence of an adverse event (AE)/ adverse drug reaction (ADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of a serious AE (SAE)/ serious ADR (SADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of an unexpected AE (UAE)/ unexpected ADR (UADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of a serious unexpected AE (SUAE)/ serious unexpected ADR (SUADR)

Timeframe: At least 28 days from the last dose of Elranatamab

Incidence of an adverse event special interest (AESI)

Timeframe: At least 28 days from the last dose of Elranatamab